Trial · NCT06687265
Effects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension
NCT06687265, Phase 2, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension. Trials, record NCT06687265. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06687265
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension
- NCT number
- NCT06687265
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 76 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Cirrhosis, Portal Hypertension Related to Cirrhosis
- Interventions
- Metformin, Placebo
- First posted
- 2024-11-13
- Last updated
- 2025-04-13
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | effect of metformin versus placebo during 28 days on HVPG, in patients with cirrhosis and a HVPG ≥ 12 mm Hg already treated with carvedilol. | after 28 days of treatment | HVPG measures before and after metformin or placebo treatment |
| Secondary | the rate of patients with a clinically significant improvement in HVPG | after 28 days of treatment | Change in arterial pressure after treatment : HVPG \> or = 12 mm Hg, or at least a 10% reduction from baseline, |
| Secondary | Change in cirrhosis severity MELD score | after 28 days of treatment | MELD (Model for End-Stage Liver Disease) score classification (6-40 with high score is worse outcome) |
| Secondary | Change in cirrhosis severity Child-Pugh score | after 28 days of treatment | Child-Pugh classification or Child-Turcotte-Pugh classification (5-15 with high score is worse outcome) |
| Secondary | change in systemic haemodynamics | after 28 days of treatment | The size (diameter) of a blood vessel. |
| Secondary | the tolerability of metformin in patients with cirrhosis and a HVPG ≥ 12 mm Hg | after 28 days of treatment | treatment compliance |
| Secondary | Maximum metformin plasma level | after 28 days of treatment | plasma level (at 2h30 of last dose) |
| Secondary | Relative changes in HVPG | day 28 | HVPG measure |
| Secondary | Change in arterial pressure | after 28 days of treatment | HVGP |
| Secondary | the safety of metformin in patients with cirrhosis and a HVPG ≥ 12 mm Hg | 30 days after the beginning of treatment | complication and adverse event evaluate by CTCAE guideline during treatment |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 34165199 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06687265
GET https://conductscience.org/api/trials/v1/NCT06687265/registered